Ribon

Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA

Retrieved on: 
Thursday, August 10, 2023
University, University of Nebraska Medical Center, Doctor of Philosophy, Nebraska Medicine, Babson College, MBA, Carroll School of Management, Cubist Pharmaceuticals, Boston College Law School, Pear, Ribon, Cell biology, Memorial, Merck, FDA, Therapy, Management, Auron, Biochemistry, Cerulean, Chemistry, Sanofi

Victoria Richon, Ph.D., was appointed to the company’s board of directors.

Key Points: 
  • Victoria Richon, Ph.D., was appointed to the company’s board of directors.
  • Christopher Guiffre, J.D., MBA, was appointed president and chief operating officer.
  • “We are thrilled to welcome Vicky and Chris to the Auron team during this exciting time for the company,” said Kate Yen, Ph.D., founder and chief executive officer of Auron.
  • Christopher Guiffre, J.D., MBA, joins Auron from Pear Therapeutics where he served as chief financial officer and chief operating officer since 2017.

Terray Therapeutics Strengthens Leadership with Appointment of Sudha Parasuraman, MD to its Board of Directors

Retrieved on: 
Tuesday, May 16, 2023
Boston Children's Hospital, University, Dana–Farber Cancer Institute, Cone Health Women's Hospital, Biotechnology, University of Madras, St. Jude Children's Research Hospital, Sudha, Children's Hospital of Michigan, Child, Ribon, Harvard Medical School, Bortezomib, Ribociclib, Novartis, Inflammation, Hematology, Drug discovery, Hospital, Rare, Therapy, Independent Board for Presbyterian Foreign Missions, Management, Pharmaceutical industry, Lionel Terray, Brigham, MD

PASADENA, Calif., May 16, 2023 /PRNewswire/ -- Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale, today announced the appointment of Sudha Parasuraman, MD, as an Independent Director.

Key Points: 
  • "We are tremendously excited to have Sudha join our Board of Directors," said Jacob Berlin, Ph.D., Chief Executive Officer of Terray.
  • "As Terray's internal and partnered programs move towards the clinic, we are fortunate to be able to draw on Sudha's deep clinical and strategic expertise."
  • "I am thrilled to join the Terray Board of Directors and work with the talented team of scientists they have assembled," said Dr. Parasuraman.
  • I look forward to bringing my strategic perspective on translational science, clinical development, and company-building to Terray."

Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim

Retrieved on: 
Tuesday, November 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Enzyme, Ribon, Inflammation, Therapy, Patient, Boehringer Ingelheim, Disease, CD38, Biology, Acquisition, Pharmaceutical industry

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim.
  • Boehringer Ingelheim aims to develop novel therapies based on Ribons CD38 program to transform the lives of patients with immunological and fibrotic diseases.
  • Ribon has developed this program from target and lead discovery through lead optimization using its proprietary BEACON+ platform.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, International Congress on Tuberculosis, Inflammation, Program, Enzyme, Therapy, Disease, ERS, T helper 17 cell, Tissue, Pathology, European Respiratory Society, Asthma, Skin, Neutrophil, Ribon, Lung, Cytokine, PARP, Biology, R gene, International, Eosinophil, Atopic dermatitis, STAT6, STAT3, Trial of the century, Patient, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Vaccine

The data were presented in a late-breaking poster titled The PARP14 Inhibitor RBN-3143 Suppresses Lung Inflammation in Preclinical Models at the European Respiratory Society (ERS) International Congress 2022.

Key Points: 
  • The data were presented in a late-breaking poster titled The PARP14 Inhibitor RBN-3143 Suppresses Lung Inflammation in Preclinical Models at the European Respiratory Society (ERS) International Congress 2022.
  • Data presented in the ERS International Congress 2022 presentation include results from preclinical studies evaluating RBN-3143 in a steroid-resistant model of allergic lung inflammation, as well as additional models of inflammatory disease.
  • The ERS International Congress 2022 presentation is available on the Ribon Therapeutics corporate website via the following link: https://ribontx.com/publications/ .
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis

Retrieved on: 
Tuesday, March 22, 2022
Biotechnology, Health, Oncology, Clinical Trials, Inflammation, Cell, Therapy, Eosinophil, Cytokine, T helper 17 cell, Â, Trial of the century, R gene, Research, Program, Pathology, Enzyme, Psoriasis, Tissue, Biology, NAD, Neutrophil, News, Asthma, Ribon, Atopic dermatitis, Patient, Disease, Pharmaceutical industry

RBN-3143 is a novel, orally administered, first-in-class inhibitor of PARP14 with potential as a therapy in a range of inflammatory diseases, with an initial focus in atopic dermatitis.

Key Points: 
  • RBN-3143 is a novel, orally administered, first-in-class inhibitor of PARP14 with potential as a therapy in a range of inflammatory diseases, with an initial focus in atopic dermatitis.
  • As a first-in-class, oral small molecule inhibitor of PARP14, RBN-3143 has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases.
  • RBN-3143 is currently being evaluated in a Phase 1 clinical study in healthy volunteers and atopic dermatitis patients.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer

Retrieved on: 
Tuesday, November 16, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Lists of diseases, Cornell University, Therapy, Commercial, Ribon, Entrepreneurship, CEO, MBA, Immune system, Doctor of Philosophy, Harvard Medical School, SVP, George Church, CBO, Instagram, Facebook, NSAA, Commensalism, Twitter, Merrimack Pharmaceuticals, Biotechnology, Company, LinkedIn, Business development, Patient, FDA, Pharmaceutical industry

GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward Tad Stewart , who joins the team as Chief Business Officer (CBO).

Key Points: 
  • GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward Tad Stewart , who joins the team as Chief Business Officer (CBO).
  • Mr. Stewart has worked extensively in business and corporate development in the biotechnology and pharmaceutical space for more than 20 years.
  • He has played an integral strategic role in scaling platform biotechnology companies from early stages through FDA-approval and product launch.
  • Mr. Stewart served most recently as Chief Business Officer of Ribon Therapeutics.

Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech

Retrieved on: 
Monday, September 27, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Biotechnology, Therapy, Inflammation, Society, NAD, Cancer, Patient, Annual general meeting, SCCL, Biology, American Society of Clinical Oncology, Managing editor, ASCO, Medicine, Ribon, Disease, Enzyme, Industry, Lung, Fine chemical, Pharmaceutical industry

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been named by Fierce Biotech as one of 2021s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been named by Fierce Biotech as one of 2021s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
  • We are thrilled to be recognized by Fierce Biotech among the industrys leading innovators, reflecting the potential of our novel pipeline and approach.
  • Speaking with this years class of Fierce 15 winners showed us that not even a global pandemic can stop incredible innovations in medicine.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Ribon Therapeutics Announces Key Management Promotions

Retrieved on: 
Wednesday, September 1, 2021
Biotechnology, Health, Professional Services, Clinical Trials, Human Resources, BRAF, Melanoma, Epithelioid sarcoma, Pharmacology, Therapy, Cancer, NAD, Cell biology, CSO, Leadership, McGovern Medical School, Harvard Medical School, University of Jena, Boston College, Merck, Research, Drug discovery, AKT, Disease, Martin Luther University of Halle-Wittenberg, Inflammation, Follicular lymphoma, EZH2, Enzyme, Patient, GlaxoSmithKline, Molecular Discovery, US, Â, Ribon, Trinity University, GSK, Pharmaceutical industry

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer.
  • We have made significant progress advancing our clinical trial program for RBN-2397, developing RBN-3143 through IND-enabling studies and identifying additional NAD+-utilizing enzyme targets, said Heike Keilhack, Ph.D., Chief Scientific Officer, Ribon Therapeutics.
  • I am excited to take on the new role of CSO as we leverage our proprietary platform to discover first-in-mechanism therapeutics.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.